drugset
drugset / Trial / NCT04627064

ABEMA Alone or in COMBO With MK-6482

NCT04627064 ↗

Phase 1 Completed 11 enrolled Dana-Farber Cancer Institute Eli Lilly and Company · collabNational Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC). The names of the study drugs in this investigational combination are: * Abemaciclib * MK-6482

Timeline

Start
2020-12-31
Primary completion
2024-02-09
Completion
2024-08-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule — Oral
Subject Belzutifan Small molecule — Oral

Indications

clear cell renal carcinoma